Development of validated stability-indicating chromatographic method for the determination of fexofenadine hydrochloride and its related impurities in pharmaceutical tablets

A simple reversed phase high performance liquid chromatographic method with diode array detector (HPLC-DAD) has been developed and subsequently validated for the determination of fexofenadine hydrochloride (FEX) and its related compounds; keto fexofenadine (Impurity A), meta isomer of fexofenadine (Impurity B), methyl ester of fexofenadine (Impurity C) in addition to the methyl ester of ketofexofenadine (Impurity D). The separation was based on the use of a Hypersil BDS C-18 analytical column (250 × 4.6 mm, i.d., 5 μm). The mobile phase consisted of a mixture of phosphate buffer containing 0.1 gm% of 1-octane sulphonic acid sodium salt monohydrate and 1% (v/v) of triethylamine, pH 2.7 and methanol (60:40, v/v). The separation was carried out at ambient temperature with a flow rate of 1.5 ml/min. Quantitation was achieved with UV detection at 215 nm using lisinopril as internal standard, with linear calibration curves at concentration ranges 0.1-50 μg/ml for FEX and its related compounds. The optimized conditions were used to develop a stability-indicating HPLC-DAD method for the quantitative determination of FEX and its related compounds in tablet dosage forms. The drugs were subjected to oxidation, hydrolysis, photolysis and heat to apply stress conditions. Complete separation was achieved for the parent compounds and all degradation products. The method was validated according to ICH guidelines in terms of accuracy, precision, robustness, limits of detection and quantitation and other aspects of analytical validation

Synchronous Presentation of Two Extranodal Lymphomas: Follicular Lymphoma and Extranodal Marginal Zone Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALToma)

Synchronous malignancies are rare conditions in oncology practices, generally seen as solid tumors with hematological neoplasms. However, occurrence of two different hematological malignancies in the same patient is extremely rare. Two primary malignancies should be considered especially in patients with extraordinary presentations and treatment resistance. © 2018 Polish Society of Hematology and Transfusion Medicine, Insitute of Hematology and Transfusion Medicine, Published by Sciendo 2018

2023DE DÜNYA: NÜFUS, SERMAYE PİYASALARI ve EKONOMİK BÜYÜKLÜK İLE TAHMİN EDİLMESİ

Bu çalışma iki amaca odaklanmaktadır.Çalışmanın ilk amacı; nüfusta, yoksul nüfusta ve sermaye piyasalarının gelişiminde meydana gelen değişim ile GSYİHde meydana gelen değişim arasındaki ilişkiyi belirlemektir. Çalışmanın ikinci amacı ise belirlenen ilişkileri kullanarak ülkelerin 2023 yılındaki durumunu tahmin etmektir. İlgili değişkenler arasındaki ilişkileri belirlemek için 135 ülkenin 1980 ile 2010 yılları arasındaki verileri analiz edilmiştir. Analiz sonuçları, nüfustaki değişim ile sermaye piyasasındaki gelişimin GSYİH üzerinde istatistiki olarak anlamlı bir etkiye sahip olduğunu ortaya koymuştur. Ayrıca, nüfustaki artış ile yoksulluk arasında da istatistiki olarak anlamlı bir ilişki bulunmuştur. Bunun yanında; E7 ülkelerinde beklenen gelişimin, G7 ülkelerindeki beklenen gelişimden daha fazla olduğu ortaya konulmuştur.This study focuses on two aims. First aim of the study is to determine the relationship between change in population, poor population and capital markets development with change in GDP. The second aim is to forecast the position of countries in 2023 by using determined relations. To determine the relationships, data of 135 countries between 1980 and 2010 were analyzed. Analysis results revealed that population changes and capital market development have a statistically significant effect on GDP. In addition, there is a statistically significant relationship between population growth and poverty. In addition, it is stated that development of E7 countries will become higher than the development of G7 countries

Acute monoblastic leukemia presenting with multiple granulocytic sarcoma nodules [Granülositik sarkom nodülleri ile ortaya çıkan bir akut monoblastik lösemi olgusu]

PubMed ID: 27094724[No abstract available

Prospective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): The Turkish hematology research and education group (ThREG)-TMA02 study

Thrombotic microangiopathy(TMA) is a pathological diagnosis characterized by abnormalities of small vessels leading to microvascular thrombosis of arterioles and capillaries. The current prospective, non-interventional, multicenter (n:18) study aimed to define distribution of different TMA forms in adult Turkish patients who were referred for therapeutic plasma exchange (TPE) for a presumptive diagnosis of TMA. Patients with serum ADAMTS13 activity 10 %, normal renal function and no secondary TMA were treated as unclassified TMA. The study included a total of 97 patients (female: 60; male: 30) with a median age of 48 (18?74). Detailed evaluation at 1 month after hospital admission revealed aTTP, secondary TMA, infection/complement-associated hemolytic uremic syndrome and unclassified TMA in 32 (33 %), 33 (34 %), 26 (27 %) and 6 (6%) patients respectively. As subclassification of various TMAs will dictate specific therapy, proper diagnosis in a timely manner is of utmost clinical significance. © 2021 Elsevier LtdThe present study was designed as an investigator initiated trial (IIT) and sponsored by Alexion Pharmaceuticals (Tracking number: 100064)Alexion Pharmaceuticals: 10006

Therapeutic Drug Monitoring in Pediatric Patients Treated with Anti-Tuberculosis Medications by High Performance Liquid Chromatography

© 2022 Marmara University Press.The aim of this study is to perform therapeutic drug monitoring for isoniazid (INH), rifampicin (RIF), and pyrazinamide (PZA) in pediatric tuberculosis patients. The study was carried out in 3 different training-research hospitals in Istanbul, Türkiye between 2011 and 2012. The pediatric patients (aged ≤14 years) who initiated the standard primary anti-tuberculosis therapy were included in this study. The serum samples were collected 3 hours after the first medication doses were given on the 5th day of treatment. Chromatographic experiments were performed on an Agilent 1100 High-Performance Liquid Chromatography (HPLC) system, and the separation was carried out on a Nova-Pak C18 (3.9x150 mm, 5 μm, Merck) analytical column. In this HPLC method, the gradient elusion delivered 3% to 40% (v/v) acetonitrile in phosphate buffer was used, and diode array detector. Twenty-three children (60.9% male) patients were included with a mean age of 111.70 ± 59.94 months. Plasma levels were measured sub-therapeutically for INH in 14, RIF in 10, and PZA in 5 patients, according to the normal range of adult patients. Maximum plasma concentrations after three hours were found between 0.53-14.02 mg/L for INH, 11.17-60.39 mg/L for PZA, 2.15-16.75 mg/L for RIF. In conclusion, this method has been successfully applied to simultaneously determine RIF, INH, and PZA plasma levels in pediatric tuberculosis patients. RIF and INH plasma levels were found to be lower in pediatric patients with tuberculosis compared to target range of adult patients